Landscapes / Targets
T-cell
200 drugs act on T-cell, in 209 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs200
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | 30 Dec 2026Phase 3 trial completes | |||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Myasthenia Gravis, Generalized, Myasthaenia Gravis | ||||
| Open drug page | |||||
— |
Phase 3 | Jan 2027Phase 2 trial completes | |||
| Next date | Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Relapsed/Refractory Peripheral T Cell Lymphoma, Non-hodgkin Lymphoma | ||||
| Open drug page | |||||
— |
Phase 2/3 | Apr 2027Phase 2 trial completes | |||
| Next date | Apr 2027 · Phase 2 trial completes | ||||
| Also tested for | Myasthenia Gravis, Generalized Myasthenia Gravis and 4 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Phase 3 | 30 Nov 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Nov 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | Nov 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Systemic Anaplastic Large Cell Lymphoma | ||||
| Open drug page | |||||
— |
CSPC · Public 1093.HK |
Phase 3 | 30 Dec 2027Phase 3 trial completes | ||
| Next date | 30 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
PI3K inhibitor |
Phase 3 | Feb 2028Phase 3 trial completes | |||
| How it works | Blocks PI3K | ||||
| Next date | Feb 2028 · Phase 3 trial completes | ||||
| Also tested for | Lymphoma, Mycosis Fungoides | ||||
| Open drug page | |||||
— |
Bristol Myers Squibb · Public BMY |
Phase 3 | 17 May 2028Phase 2 trial completes | ||
| Next date | 17 May 2028 · Phase 2 trial completes | ||||
| Also tested for | Systemic Sclerosis, Systemic Lupus Erythematosus and 4 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | Jan 2029Phase 1/2 trial completes | |||
| Next date | Jan 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Pemphigus Vulgaris, Systemic Sclerosis and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | Jun 2029Phase 3 trial completes | |||
| Next date | Jun 2029 · Phase 3 trial completes | ||||
| Also tested for | AML, MDS | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Jul 2029Phase 3 trial completes | |||
| Next date | 30 Jul 2029 · Phase 3 trial completes | ||||
| Also tested for | PTCL | ||||
| Open drug page | |||||
Human immunoglobulin G |
Phase 3 | 27 Sep 2029Phase 3 trial completes | |||
| Next date | 27 Sep 2029 · Phase 3 trial completes | ||||
| Also tested for | Secondary Immune Deficiency | ||||
| Open drug page | |||||
Gene therapy substances |
Phase 3 | Dec 2029Phase 3 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | Dec 2029 · Phase 3 trial completes | ||||
| Also tested for | Large B-cell Lymphoma, Lymphoma, B-Cell and 7 more | ||||
| Open drug page | |||||
PD-L1 antibody |
CStone · Public 2616.HK |
Phase 3 | Dec 2029Phase 3 trial completes | ||
| Next date | Dec 2029 · Phase 3 trial completes | ||||
| Open drug page | |||||
Histone deacetylase inhibitor |
Phase 3 | Jul 2030Phase 3 trial completes | |||
| How it works | Blocks HDAC enzymes | ||||
| Next date | Jul 2030 · Phase 3 trial completes | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
Folate analog metabolic inhibitor |
Phase 3 | Jul 2030Phase 3 trial completes | |||
| Next date | Jul 2030 · Phase 3 trial completes | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 2/3 | Nov 2030Phase 2/3 trial completes | |||
| Next date | Nov 2030 · Phase 2/3 trial completes | ||||
| Also tested for | Glioblastoma Multiforme of Brain | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2032Phase 3 trial completes | |||
| Next date | Dec 2032 · Phase 3 trial completes | ||||
| Open drug page | |||||
PI3K inhibitor |
Phase 2/3 | — | |||
| How it works | Blocks PI3K | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | — | ||
| Also tested for | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 196 of 200 drugs. The other 4 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026